What is HC Wainwright’s Estimate for TEVA FY2026 Earnings?

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) – Equities research analysts at HC Wainwright raised their FY2026 EPS estimates for Teva Pharmaceutical Industries in a research note issued on Wednesday, November 4th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings of $1.96 per share for the year, up from their previous forecast of $1.94. HC Wainwright has a “Buy” rating and a $52.00 price objective on the stock. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $1.97 per share. HC Wainwright also issued estimates for Teva Pharmaceutical Industries’ Q4 2026 earnings at $0.64 EPS, Q1 2027 earnings at $0.63 EPS, Q2 2027 earnings at $0.74 EPS, Q3 2027 earnings at $0.79 EPS, Q4 2027 earnings at $0.91 EPS and FY2027 earnings at $3.07 EPS.

A number of other research analysts have also weighed in on the company. TD Cowen raised their price objective on Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the company a “buy” rating in a research report on Wednesday, November 4th. Piper Sandler boosted their target price on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 28th. UBS Group increased their price target on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a “buy” rating in a research note on Friday, September 4th. JPMorgan Chase & Co. raised their price target on Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the company an “overweight” rating in a report on Monday, October 12th. Finally, Weiss Ratings raised Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c+)” rating in a research note on Wednesday, November 4th. Thirteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $47.23.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE TEVA opened at $42.38 on Wednesday. The company has a market cap of $49.38 billion, a P/E ratio of 98.55, a P/E/G ratio of 4.04 and a beta of 0.97. Teva Pharmaceutical Industries has a 52-week low of $24.01 and a 52-week high of $43.34. The company has a debt-to-equity ratio of 1.59, a quick ratio of 0.74 and a current ratio of 0.95. The firm’s fifty day moving average is $39.75 and its two-hundred day moving average is $34.90.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Tuesday, November 3rd. The company reported $0.86 EPS for the quarter, topping the consensus estimate of $0.72 by $0.14. Teva Pharmaceutical Industries had a net margin of 2.94% and a return on equity of 33.20%. The firm had revenue of $4.39 billion for the quarter, compared to the consensus estimate of $4.23 billion. During the same quarter in the previous year, the firm earned $0.78 earnings per share. The company’s quarterly revenue was down 1.9% compared to the same quarter last year.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Root Financial Partners LLC bought a new stake in Teva Pharmaceutical Industries in the third quarter worth $33,000. Cornerstone Planning Group LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 547.1% in the 1st quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock worth $27,000 after acquiring an additional 755 shares during the last quarter. Western Wealth Management LLC purchased a new position in shares of Teva Pharmaceutical Industries during the 1st quarter worth about $43,000. Sunbelt Securities Inc. purchased a new position in shares of Teva Pharmaceutical Industries during the 1st quarter worth about $45,000. Finally, CX Institutional purchased a new position in shares of Teva Pharmaceutical Industries during the 2nd quarter worth about $54,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Insider Transactions at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 367,600 shares of the company’s stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $39.06, for a total transaction of $14,358,456.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Mark Sabag sold 46,000 shares of the stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $41.93, for a total transaction of $1,928,780.00. Following the completion of the transaction, the insider directly owned 80,760 shares of the company’s stock, valued at approximately $3,386,266.80. The trade was a 36.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 420,942 shares of company stock worth $16,572,473 in the last three months. Insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.